Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Contract Liabilities — Deferred Revenue by Year
Total Contract Liabilities — Deferred Revenue ($M) ($M)
Natera Total Contract Liabilities — Deferred Revenue: $42.0M in FY2025, up 14.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Total current and noncurrent contract liabilities (deferred revenue) from biopharma clinical trial milestones, licensing agreements, and prepayments ($64.25M at Q2 2026).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Contract Liabilities — Deferred Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.0 | +14.7% | Form 10-Q (2026-08-07) ↗ |
| FY2024 | Dec 31, 2024 | 36.6 | +2.4% | Form 10-Q (2026-08-07) ↗ |
| FY2023 | Dec 31, 2023 | 35.7 | +16.1% | Form 10-K (2026-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 30.8 | +7.2% | Form 10-K (2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 28.7 | -60.6% | Form 10-K (2024-02-29) ↗ |
| FY2020 | Dec 31, 2020 | 72.9 | -8.6% | Form 10-K (2023-03-01) ↗ |
| FY2019 | Dec 31, 2019 | 79.8 | +80.6% | Form 10-K (2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 44.2 | +3,012.0% | Form 10-K (2020-03-02) ↗ |
| FY2017 | Dec 31, 2017 | 1.42 | – | Form 10-K (2019-03-15) ↗ |
Breakdown
What makes up total Contract Liabilities — Deferred Revenue
- Deferred Revenue, Current ($M)24.9 · FY2025
- Deferred Revenue, Long-Term / Noncurrent ($M)17.1 · FY2025
- Contract Liability Roll-Forward: Additions / Deferrals in Period ($M)50.5 · FY2025
- Contract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M)-19.2 · FY2025
- Contract Liability Roll-Forward: Revenue Recognized from Same-Period Deferrals ($M)-25.9 · FY2025
- BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025]0.50 · FY2024
- BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025]16.8 · FY2024
- Foundation Medicine Collaboration — Current Contract Liability ($M) [legacy through Q3 2025]1.70 · FY2024
- Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025]13.7 · FY2023
- BGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025]20 · FY2024
- Qiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019]40 · FY2018
Cite this data
StockData. (2026). Natera Total Contract Liabilities — Deferred Revenue ($M), annual FY2017–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-total
See every metric in the Natera KPI table. Data updated Nov 2, 2026.